Literature DB >> 2306961

Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia.

A Ortqvist1, M Kalin, L Lejdeborn, B Lundberg.   

Abstract

A model for performing fiberoptic bronchoscopy as a supplement to noninvasive diagnostic methods, in patients with community-acquired pneumonia, was prospectively studied. Twenty-four patients underwent bronchoscopy, seven pilot patients and 17 of 277 (6 percent) consecutive patients with CAP. Indications for FOB were early therapy failure (less than or equal to 72h)(n = 7), late therapy failure (greater than 72h)(n = 11), or before start of antibiotic therapy in severely ill or immunocompromised patients (n = 6). Samples were obtained by aspiration of bronchial secretion and with a protected brush catheter from which quantitative cultures with a detection level of 10(4) colony forming units per ml were performed. Results concluded that FOB, with the use of quantitative PB-cultures, offered a safe and specific diagnostic tool, which on special indications, can be of great value in the management of patients with CAP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306961     DOI: 10.1378/chest.97.3.576

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

Review 1.  Diagnosis of pneumonia and monitoring of infection eradication.

Authors:  M Ruiz; C Arosio; P Salman; T T Bauer; A Torres
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Accuracy and precision of quantitative calibrated loops in transfer of bronchoalveolar lavage fluid.

Authors:  J A Jacobs; E I De Brauwer; E I Cornelissen; M Drent
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 3.  The pulmonary physician in critical care . 3: critical care management of community acquired pneumonia.

Authors:  S V Baudouin
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

4.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  Nasopharyngeal culture in the pneumonia diagnosis.

Authors:  J Hedlund; A Ortqvist; M Kalin
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

6.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

7.  Respiratory tract colonization and incidence of secondary infection during hospital treatment of community-acquired pneumonia.

Authors:  A Ortqvist; S Hammers-Berggren; M Kalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

8.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

9.  Diagnostic value of bronchoalveolar lavage in patients with opportunistic and nonopportunistic bacterial pneumonia.

Authors:  K Dalhoff; J Braun; H Hollandt; R Lipp; K J Wiessmann; R Marre
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

10.  Topographical continuity of bacterial populations in the healthy human respiratory tract.

Authors:  Emily S Charlson; Kyle Bittinger; Andrew R Haas; Ayannah S Fitzgerald; Ian Frank; Anjana Yadav; Frederic D Bushman; Ronald G Collman
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.